Summit Therapeutics announces that planned extension phase of their PhaseOut trial, will go ahead.

Summit are going to continue their planned extension of the PhaseOut DMD study.Read more

Swapping sectors is good….

On International Women's Day we would like to share a blog written by Fiona Lawrence, our Director of Research and Clinical Development. Fiona takes a look back at her year with Duchenne UK.Read more

A Call To Action

The European Medicines Agency wants to know about your direct experiences with Duchenne, and what the impact of having access to Exondys 51 may have on you and your family. Read our guide to submitting patient input.Read more

Rare Disease Day 2017

Today is Rare Disease Day, it takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives.Read more

Duchenne UK funds research into the repurposing of an anti-inflammatory drug to potentially promote muscle strength and movement

Duchenne UK is funding research into montelukast as a potential therapy for Duchenne Muscular DystrophyRead more

Heart Specialist joins Duchenne UK Scientific Board

Dr John Bourke joins our Scientific Advisory Board. He is a leading cardiologist with a specialist interest in treating and monitoring inherited neuromuscular disorders including Duchenne Muscular Dystrophy.Read more

Leading Research Director Joins Board of Trustees at Duchenne UK

Maria Hassard, our new Trustee, is the Deputy Director of Research at the globally renowned Moorfields Biomedical and Clinical Research Centre in London.Read more

Duchenne UK announces a new grant to Oxford University to investigate improved delivery of exon skipping drugs

Duchenne UK is pleased to announce its support of the development of the next generation of exon skipping drugsRead more

Duchenne UK hosts an industry workshop on Economic Modelling for HTA

The aim of the day was to work with companies developing potential treatments for DMD to best deal with the NICE processRead more

Fiona Lawrence is interviewed by Partnerships in Clinical Trials

Our Director of Research and Clinical Development discusses the challenges and innovations impacting rare disease research todayRead more

Duchenne UK participates in the recent NICE/ NHS England consultation

Update on Duchenne UK's participation in the recent NICE and NHS England consultation on changes for evaluating and funding drugs and other health technologiesRead more